Dendreon Announces First Quarter 2013 Results

SEATTLE--(BUSINESS WIRE)--May 9, 2013--Dendreon Corporation (Nasdaq:DNDN) today reported results for the first quarter ended March 31, 2013. Net product revenue for the quarter was $67.6 million compared to $82.0 million for the quarter ended March 31, 2012, down 17.6% year over year.

Net loss in the first quarter of 2013 was $72.0 million, or $0.48 per share, compared to a net loss of $103.9 million, or $0.70 per share for the same period in 2012.

As of March 31, 2013, Dendreon had $337.3 million in cash, cash equivalents, and short-term and long-term investments, compared to $429.8 million as of December 31, 2012.

"We remain focused on improving PROVENGE utilization by executing our direct-to-consumer campaign which began in March, educating potential patients in the mCRPC market and employing our enhanced sales messaging with our customers," said John H. Johnson, chairman, president and chief executive officer. "Currently, we are seeing an improvement in enrollments, a trend which began mid-way through the first quarter. As we leverage the power of our DTC campaign, we are confident in our ability to grow PROVENGE year over year."

First Quarter Highlights:

  • Continued new physician interest in PROVENGE® (sipuleucel-T):
    • Added 33 net new accounts in the first quarter, bringing total number of accounts that have infused to 835
  • Demonstrated positive early indicators in effectiveness of direct-to-consumer advertising:
    • Addresses significant need for patient education and awareness
    • First national TV commercial aired March 7
    • Patients contacting Dendreon directly for more information, resulting in a significant increase in call center and relationship marketing activity
  • Continued improvement in reimbursement landscape for physicians:
    • Reported average time to payment remains less than 30 days for physicians
  • Continued progress with strategic restructuring:
    • The Company believes it can reduce cost of goods sold (COGS) to below 50% of net product revenue in the third quarter 2013 at its current forecast levels
    • Already seeing net benefits in financial results associated with the restructuring initiatives and expect full benefits realized in the third quarter of 2013
  • Continued focus on expanding clinical data:
    • Presented data at AUA that further analyzed Phase III IMPACT data to identify prognostic variables that may support early administration of PROVENGE after diagnosis of metastatic castrate resistant prostate cancer
    • Actively evaluating partnering strategies for European expansion; continuing to enroll patients in the sipuleucel-T European Union open-label study; expect a regulatory decision in Europe in the second half of 2013
    • Completed enrollment of PROVENGE and ADT sequencing study; presented initial data at ASCO-GU and expect to present additional data in 2013
    • Completed enrollment of PROVENGE and Zytiga® (abiraterone) sequencing study; presented initial data at ASCO-GU and expect to present additional data in 2013
    • Supporting 19 novel investigator initiated trials (IITs) to advance understanding of immunotherapy and the treatment of advanced prostate cancer
    • Named steering committee for Phase II trial for sequencing PROVENGE with Xtandi® (enzalutamide) and expect to begin enrolling patients in the fourth quarter of 2013

Conference Call Information

Dendreon will host a conference call on May 9, 2013 at 9:00 a.m. ET. To access the live call, dial 1-877-548-9590 (domestic) or +1-720-545-0037 (international); the conference ID number is 53497612. The call will also be audio webcast with supplemental information slides available from the Company's website at under the "Investor/Webcasts and Presentations" section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-585-8367 or +1-404-537-3406 for international callers; the conference ID number is 53497612. The replay will be available from 12:00 p.m. ET on Thursday, May 9, 2013 until 11:59 p.m. ET on Wednesday, May 15, 2013. In addition, the webcast will be archived for on-demand listening for 90 days at and the supplemental information slides will be posted to the Company's website.

PROVENGE Indication and Important Safety Information

PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

The safety evaluation of PROVENGE was based on 601 prostate cancer patients in four randomized clinical trials who underwent at least one leukapheresis. The most common adverse events (incidence greater-than or equal to 15%) are chills, fatigue, fever, back pain, nausea, joint ache, and headache. Serious adverse events reported in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. In controlled clinical trials, severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

To fulfill a post marketing requirement and as a part of the company's ongoing commitment to patients, Dendreon will conduct a registry of approximately 1500 patients to further evaluate a small potential safety signal of cerebrovascular events. In four randomized clinical trials of PROVENGE in prostate cancer patients, cerebrovascular events were observed in 3.5% of patients in the PROVENGE group compared with 2.6% of patients in the control group.

For more information on PROVENGE, please see the full prescribing information at or call 1-877-336-3736.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington, and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements regarding the expected benefits of the restructuring, the timing and elements of the restructuring, the timing and form of related charges, the expected annual operating expense reduction, expectations and beliefs regarding Dendreon's financial position, profitability and Dendreon's ability to break even and achieve improved performance as a result of the restructuring, expectations regarding reductions of cost of goods sold, expectations regarding regulatory approval of PROVENGE® in Europe, expectations regarding the presentation of clinical data, developments affecting Dendreon's U.S. and global business and prospects, beliefs and expectations regarding potential revenue and earnings from product sales, including beliefs regarding Dendreon's ability to grow sales, expectations regarding market size, target market, and market opportunity, beliefs regarding the impact of our direct to consumer advertising, expectations with respect to our sales force execution and effectiveness, progress generally on commercialization efforts for PROVENGE, and expectations about clinical trial enrollments. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause Dendreon's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, our inability to achieve and sustain commercial success for PROVENGE; the identification of efficacy, safety or other issues with PROVENGE; a slower than anticipated adoption by treating physicians of PROVENGE for the treatment of patients with advanced prostate cancer for a variety of reasons, including competing therapies, instability in our sales force, the risk that we cannot replace vacant sales positions on a prompt basis, perceived difficulties in the treatment process, delays in obtaining reimbursement or for other reasons; any promotional limitations imposed by the FDA on our ability to commercialize and market PROVENGE; unexpected difficulties and costs associated with the rapid expansion of our commercial operations to support the commercial launch of PROVENGE; the impact of competing therapies on sales of PROVENGE, the failure to achieve approval in Europe, manufacturing difficulties, disruptions or delays and other factors discussed in the "Risk Factors" section of Dendreon's Annual Report on Form 10-Q for the quarter ended March 31, 2013. All forward-looking statements are qualified in their entirety by this cautionary statement. Dendreon is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

(in thousands, except per share amounts)
          Three Months Ended
          March 31,
          2013   2012
Product revenue, net         $ 67,580   $ 81,972
Royalty and other revenue           14     102
Total revenue           67,594     82,074
Operating expenses:              
Cost of product revenue           43,375     60,041
Research and development           18,448     17,343
Selling, general and administrative           62,446     95,315
Restructuring and contract termination           1,960     (124)
Total operating expenses           126,229     172,575
Loss from operations           (58,635)     (90,501)
Interest income           218     383
Interest expense           (13,629)     (13,812)
Other income           41     16
Net loss         $ (72,005)   $ (103,914)
Basic and diluted net loss per share         $ (0.48)   $ (0.70)

Shares used in computation of basic and diluted net loss per share

          151,481     147,599
          March 31,   December 31,
          2013   2012
Balance Sheet Data:              
Cash and cash equivalents         $ 130,577   $ 188,408
Short-term investments           144,634     165,396
Long-term investments           62,059     76,045
Total cash and cash equivalents, short-term investments and long-term investments           337,270     429,849
Trade accounts receivable           39,109     38,884
Inventory           89,542     76,300
Total assets           638,950     721,119
Convertible senior notes due 2016           539,140     532,744
Convertible senior subordinated notes due 2014           27,685     27,685
Total stockholders' equity (deficit)           (35,907)     34,613
(in thousands, except per share amounts)
          Three Months Ended
          March 31,
          2013         2012  
GAAP net loss         $ (72,005 )       $ (103,914 )
Non-GAAP adjustments:                  
Depreciation and amortization expense           7,762           10,864  

Imputed interest related to the convertible senior notes due 2016

          6,396           5,898  
Restructuring and contract termination, including stock-based compensation expense           1,960           (124 )

Management severance and other termination benefits:

Severance expense                     5,173  
Non-cash stock-based compensation expense                     11,678  
Other stock-based compensation expense           2,082           19,475  
Non-GAAP net loss         $ (53,805 )       $ (50,950 )
Non-GAAP net loss per share- basic and diluted         $ (0.36 )       $ (0.35 )

Shares used in computation of basic and diluted net loss per share

          151,481           147,599  

The above table provides certain non-GAAP financial measures that include adjustments to GAAP figures. Dendreon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Dendreon's financial performance and its prospects for the future. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of operational results and trends. We believe excluding these items provides important insight into our operational results, important for a company at our stage in development. In addition, these non-GAAP financial measures are among the indicators Dendreon management uses for planning and forecasting purposes and measuring the Company's performance. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP figures.


Dendreon Corporation
Corporate Communications
Lindsay Rocco, 862-596-1304
[email protected]
Investor Relations
Nicole Soley, 206-455-2220
[email protected]